The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

By Puyaan Singh (Reuters) - The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

Advances recognized by science’s most lucrative awards include Large Hadron Collider experiments and groundbreaking ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

Maxeon Solar Technologies said it is establishing an alternative network of supply-chain partners and increasing its manufacturing capabilities in the U.S. as it deals with new tariffs and trade ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis ...